AMOEBA (EPA:ALMIB) - AMOÉBA PUBLISHES A NEW SCIENTIFIC PAPER IN THE JOURNAL MICROORGANISMS

Transparency directive : regulatory news

16/11/2020 14:30

AMOÉBA PUBLISHES A NEW SCIENTIFIC PAPER IN THE JOURNAL MICROORGANISMS

Chassieu (France), November 16 2020 - AMOÉBA (FR0011051598 - ALMIB), producer
of a biological biocide capable of eliminating the microbial risk in water and
of a biocontrol product for plant protection, still in the testing phase,
announces the publication of a new scientific publication
(https://www.mdpi.com/2076-2607/8/11/1791/pdf). This work is the result of
collaboration between the Institut Hospitalo-Universitaire (IHU) Méditerranée
Infection (Marseille) and the company Amoéba (Chassieu). The paper was
published in the microbial biotechnology section of "Microorganisms", an
international peer-reviewed scientific journal.

In order to go even further in the scientific understanding of the behavior of
the amoeba Willaertia magna C2c Maky, a comparative study of amoeba cultivation
methods was carried out in the laboratory of Professor Bernard LA SCOLA at the
IHU of Marseille. The proteomic(1) and lipidomic(2) profiles of the amoeba,
cultivated by the Amoeba company in adhesion (on support) or in suspension (in
bioreactor), were analyzed at the IHU. This work provided essential knowledge
on the development and metabolism of the amoeba industrially produced by
Amoéba. The objective was to understand how the amoeba manages to adapt to
bioreactor culture and to draw lessons to optimize its large- scale production.
Metabolic differences were observed, particularly in bioreactors where the
lipid metabolic pathway is favored.

" This study improves our understanding of the biology and molecular processes
of W. magna C2c Maky. It demonstrates the adaptability of microorganisms to
environmental changes. The amoeba adapts by promoting specific metabolic
pathways. Everything is already present in its genetic information and
according to its needs, the amoeba will favor the synthesis of the most
suitable molecules " declares Professor Bernard LA SCOLA, head of the team
behind these results at IHU Méditerranée Infection.

" This paper, published as part of Dr. Issam Hasni's thesis, complements the
previously published data on Willaertia magna C2c Maky and gives us an overview
of the proteins and lipids present in the amoeba. The information gathered will
allow us to work on the composition of the culture medium in order to make our
production process even more efficient" says Sandrine DEMANECHE, scientific
manager of Amoeba.

(1) The proteome is the set of proteins in an organism.
(2) The lipidome is all the lipids (fats) of an organism.

About AMOEBA:
Amoéba's ambition is to become a major player in the treatment of bacterial
risk in the fields of water, healthcare and plant protection. Our biological
solution is an alternative to chemical products widely used today. Amoéba is
currently focusing on the market of industrial cooling towers estimated at
EUR1.7Bn (1) on a global chemical biocide market for water treatment, evaluated
at EUR21Bn (2) and on the biocontrol market for plant protection estimated
globally at EUR1.6Bn (4). In the future, the Company is looking at developing
new applications such as chronic wound care, estimated at EUR 751 million (3)
in the USA. Sales of associated products with healthcare, biocides and crop
protection are subject to the Company being granted local regulatory market
authorizations. The Company is currently in a trial phase for biocidal and
plant protection applications and does not market any products.
Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada
and in the United States, Amoéba is quoted on Euronext Growth. The Company is
a member of the BPIfrance Excellence network and is eligible for the PEA-PME
SME equity savings plan setup. More information on www.amoeba-biocide.com.

(1): Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013
(2): Sources combined by Amoéba from water treaters, Freedonia, Eurostat et
MarketsandMarkets
(3): BCC Research, "Markets for Advanced Wound Management Technologies,"
Wellesley, MA, 2017
(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK

Contacts:
Amoéba
Valérie FILIATRE Directeur Général Adjoint
+33 4 26 69 16 00
valerie.filiatre@amoeba-biocide.com

Calyptus
Relations investisseurs & Presse
Grégory BOSSON / Mathieu CALLEUX
+33 1 53 65 37 90 /91
amoeba@calyptus.net

Disclaimer
This press release contains certain forward-looking statements concerning
AMOEBA which are based on its own assumptions and hypothesis and on information
that are available to us. However, AMOEBA gives no assurance that the estimates
contained in such forward-looking statements will be verified, which estimates
are subject to numerous risks including the risks set forth in the Universal
Registration Document of AMOEBA filed with the French Financial Markets
Authority (Autorité des Marchés Financiers) on April 30, 2020 under number
D20-0416 (a copy of which is available on www.amoeba- biocide.com). The
forward-looking statements contained in this press release are also subject to
risks not yet known to AMOEBA or not currently considered material by AMOEBA.
The occurrence of all or part of such risks could cause actual results,
financial conditions, performance or achievements of AMOEBA to be materially
different from such forward-looking statements.

Adresse : 38 Avenue des Frères Montgolfier, 69680 CHASSIEU
Société Anonyme au capital de 311 578,38 EUR
RCS Lyon 523 877 215

Tel: +33 (0)4 26 69 16 00 ? Email: contact@amoeba-nature.com
Linkedin: @amoeba-nature ? Twitter: @AmoebaNature
www.amoeba-nature.com

AMOEBA's latest news

02/05/2024 18:00

AMOEBA (EPA:ALMIB) - AMOÉBA PUBLISHES A NEW SCIENTIFIC PAPER IN THE JOURNAL MICROORGANISMS

Transparency directive : regulatory news

AMOEBA's latest news

Other stories